Q-omics provides the consensus-scored COX7A2L profile across patient tissues and cancer cell-line models. COX7A2L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, COX7A2L is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, COX7A2L protein abundance shows 22,131 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where COX7A2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX7A2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX7A2L survival associations across molecular data types. COX7A2L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX7A2L RNA expression–survival associations across cancer types. High COX7A2L expression shows unfavorable associations in LIHC, ACC, KICH, HNSC, KIRP and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for COX7A2L RNA expression.
This table summarizes COX7A2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX7A2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX7A2L shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, BRCA, CHOL and LUSC. The HNSC box plot shows higher COX7A2L RNA expression in tumor versus normal tissue (log2 FC = +0.987, t-test p < 0.001).
This table shows molecular features associated with COX7A2L in patient tissues and cancer cell lines. In patient samples, COX7A2L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, COX7A2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
